# Pharmaxon

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pharmaxon

- Industry: Biotechnology
- Headquarters: Marseille, France
- Website: www.pharmaxon.com
- Total disclosed funding: $3.2M
- Latest round: Series A (Nov 1, 2009)
- Investors on record: 4

## About

Pharmaxon specializes in providing premium domain names as valuable branding assets for businesses in the pharmaceutical and healthcare sectors, facilitating their online presence and marketing efforts.Founded in 2004 and headquartered in Marseille, France, Pharmaxon operates in the pharmaceutical and healthcare domain space. The company has made 2 significant deals, with the most recent occurring on November 1, 2009, when it raised EUR 1.7 million in Series A financing from SHAM and returning investor Primaveris. Pharmaxon focuses on enhancing the digital capabilities of its clients through strategic domain name ownership.Pharmaxon.com offers a premium domain name designed to serve as a branding asset for businesses within the pharmaceutical and healthcare sectors. This domain attracts companies such as research labs, pharmaceutical firms, medical technology startups, and healthcare providers, emphasizing its suitability for medical innovations. The core offering includes full ownership of the domain name, which comes with logo design rights and source files, providing businesses with an immediate online presence to facilitate their marketing efforts across established and emerging economies.Pharmaxon.com generates revenue primarily through the sale and lease-to-own transactions of its domain name. Clients can either purchase the domain outright or opt for a lease-to-own arrangement, enabling gradual payment over time. Upon acquisition, clients receive full DNS access for immediate use of the domain for website and email functionalities, catering to startups and established enterprises seeking to enhance their digital footprint. The pricing is reflective of the domain's premium nature, ensuring businesses recognize the investment value.Pharmaxon plans to utilize the recent EUR 1.7 million raised in Series A financing to further develop its offerings and expand into new markets. The company aims to launch new domain name products tailored to the evolving needs of clients in the healthcare sector. Additionally, Pharmaxon is targeting expansion into emerging markets in Eastern Europe and Asia by the end of 2025, focusing on regions with increasing demand for healthcare and pharmaceutical advancements.

## Funding rounds

- Series A, Nov 1, 2009, $2.5M — Relyens, Primaveris
- Seed, Oct 1, 2006, $0.6M — Esperante Ventures, Primaveris, Inserm-Transfert Initiative

## Investors

- Esperante Ventures (https://capitalatlas.ai/funds/esperante-ventures) — Seed
- Primaveris (https://capitalatlas.ai/funds/primaveris) — Seed, Series A
- Inserm-Transfert Initiative — Seed
- Relyens — Series A